Morepen Laboratories Ltd share price inched up 4.83% to Rs 132.5 after the company's net profit saw a strong growth of 57.75% to Rs 88.89 crore, while revenue from operations increased sharply by 30.94% to Rs 746.5 crore in Q3FY26 over Q2FY26.

The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.44 lakh crore, easing 4.06%. It has marginally improved by 3.17% over last one week and edged lower by 0.26% in last one month while the market capitalization of Morepen Laboratories Ltd has increased 14.42% and 134.60% in the same period respectively.

Profit before tax (PBT) of Morepen Laboratories Ltd stood at Rs 116.54 crore in Q3 FY26, rallying 155.07% year-on-year, and expanding by 56.37% quarter-on-quarter. EBITDA came in at Rs 114 crore, jumping 339.27% YoY and surging by 47.92% sequentially.

Total expenses jumped by 27.73% to Rs 633.46 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 411.91 crore, witnessing a sharp rise of 25.44% YoY, while employee benefits expense was at Rs 79.69 crore, soaring 27.63% YoY.

For the TTM ended FY26, revenue from operations declined slightly by 0.33% to Rs 1805.69 crore, while net profit fell 18.95% to Rs 95.65 crore, compared to previous TTM. EBITDA surged by 16216% to Rs 104.31 crore, and PBT plunged by 22.69% to Rs 119.92 crore compared to previous TTM.

The company's consolidated net cash flow from operating activities stood at Rs 32.64 crore in FY26, as against Rs 32.06 crore in FY25.

Morepen Laboratories Ltd soared by 173.31% in last one year, significantly outperforming the benchmark BSE Sensex which has reduced by 13.19% during the same period.